Grant: CIHR Fellowship
Direct Payment
$150,000.00
Infection-Inflammation and Activation of Novel Resolution Mediator Programs
EF 2012-13
Résumé
Uncontrolled and excessive inflammation is linked to several chronic diseases including vascular and neurological disease. Recent evidence suggests resolution of inflammation is not a passive clearance of pro-inflammatory mediators, as was once thought, but is an active process with its own anti-inflammatory and pro-resolving mediators.
Specialized Pro-resolving Mediators (SPM) including Resolvins and Protectins are a genus of bioactive mediators, produced naturally in our bodies from omega-3 fatty acids like docosahexaenoic acid (DHA) that we get in our diet. These compounds were discovered in the proposed training laboratory and potently resolve inflammation, with certain SPM 10,000 times more potent than commonly prescribed non-steroidal anti-inflammatory drugs. Structures, receptors, and target cellular pathways have been identified for several SPM in many disease models; however, the metabolism of DHA in bacterial infection and the effects of increased precursor DHA has yet to be investigated. The proposed study will test the impact of DHA and bioactive DHA metabolites in an animal model of bacterial infection, which has implications for human infection. I hypothesize that increasing DHA levels in the blood will reduce inflammation and promote resolution of bacterial infection, and that it does so though the production of novel SPM. Important for translation to the clinic, these studies will determine how long a dose of DHA can be given before infection while still promoting healthy resolution, and investigate the mechanism through which this might be happening.
This research will help to map the new terrain of inflammation resolution with the goal to better appreciate the role of nutrition in the innate immune response and infection. It will also help identify new pathways and tools from a pre-clinical model to consider for future human studies and the evaluation of novel therapies.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
279628
Name
Orr Sarah K
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Infection-Inflammation and Activation of Novel Resolution Mediator Programs
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Docosahexaenoic Acid; Inflammation Resolution; Mouse Model; Resolvins
Abstract
Uncontrolled and excessive inflammation is linked to several chronic diseases including vascular and neurological disease. Recent evidence suggests resolution of inflammation is not a passive clearance of pro-inflammatory mediators, as was once thought, but is an active process with its own anti-inflammatory and pro-resolving mediators.
Specialized Pro-resolving Mediators (SPM) including Resolvins and Protectins are a genus of bioactive mediators, produced naturally in our bodies from omega-3 fatty acids like docosahexaenoic acid (DHA) that we get in our diet. These compounds were discovered in the proposed training laboratory and potently resolve inflammation, with certain SPM 10,000 times more potent than commonly prescribed non-steroidal anti-inflammatory drugs. Structures, receptors, and target cellular pathways have been identified for several SPM in many disease models; however, the metabolism of DHA in bacterial infection and the effects of increased precursor DHA has yet to be investigated. The proposed study will test the impact of DHA and bioactive DHA metabolites in an animal model of bacterial infection, which has implications for human infection. I hypothesize that increasing DHA levels in the blood will reduce inflammation and promote resolution of bacterial infection, and that it does so though the production of novel SPM. Important for translation to the clinic, these studies will determine how long a dose of DHA can be given before infection while still promoting healthy resolution, and investigate the mechanism through which this might be happening.
This research will help to map the new terrain of inflammation resolution with the goal to better appreciate the role of nutrition in the innate immune response and infection. It will also help identify new pathways and tools from a pre-clinical model to consider for future human studies and the evaluation of novel therapies.
Competitiondate
201302
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Orr, Sarah K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~